AstraZeneca trial failures put its premium pipeline valuation at risk

AstraZeneca has long commanded one of the richest valuations among large European pharma companies, built on its reputation for consistently delivering clinical results. A recent trial failure has raised fresh questions about whether that pipeline premium is still justified. Analysts and investors are now reassessing the assumptions underpinning the company's high valuation.